Drug profile

The FDA adverse-event record for Chlorhexidine + Climbazole + Phytosphingosine

Name: Chlorhexidine + Climbazole + Phytosphingosine - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

14 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Chlorhexidine + Climbazole + Phytosphingosine. See the species affected, top reactions, and outcomes below.

14
adverse-event reports: 0.0%
death-coded share: Dog
most-reported species: 6
Erythema (for urticaria see Immune SOC) - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

0.0%

Death Rate

Active Ingredients

ChlorhexidineClimbazolePhytosphingosine

Administration Routes

Topical

Species Affected

Dog 13

Cat 1

Most Affected Breeds

Bulldog - French 3

Crossbred Canine/dog 2

Dog (other) 1

Terrier - Cairn 1

Sphynx 1

Spitz - German Pomeranian 1

Shih Tzu 1

Maltese 1

Chihuahua 1

Mixed (Dog) 1

Most Reported Reactions

Erythema (for urticaria see Immune SOC) 6

Pruritus 5

Hair coat discolouration 4

Skin irritation 2

Application site weeping (see also 'skin') 1

Rash 1

Application site rash 1

Lack of efficacy - NOS 1

Behavioural disorder NOS 1

Discomfort NOS 1

Vocalisation 1

Application site scratching 1

Outcome Breakdown

Recovered/Normal

6 (42.9%)

Outcome Unknown

6 (42.9%)

Recovered with Sequela

2 (14.3%)

Chlorhexidine + Climbazole + Phytosphingosine Adverse Event Insights

14 reports name Chlorhexidine + Climbazole + Phytosphingosine; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredients: Chlorhexidine, Climbazole, Phytosphingosine. Administration route: Topical.

By species: Dog (13 reports), Cat (1 reports). By breed: Bulldog - French (3), Crossbred Canine/dog (2), Dog (other) (1).

Leading clinical signs: Erythema (for urticaria see Immune SOC) (6), Pruritus (5), Hair coat discolouration (4), Skin irritation (2). Outcome, 14 coded reports: Recovered/Normal leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.